Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.43 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.32 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL692736 | 0.98 | CA4 (0.59) | CA4MEN1LMNAKMT2ACYP3A4 | |
| Citric Acid SCHEMBL275858 | 0.98 | CA4 (0.59) | CA4MEN1LMNAKMT2ACYP3A4 | |
| Citric Acid SCHEMBL119893 | 0.98 | CA4 (0.59) | CA4MEN1LMNAKMT2ACYP3A4 | |
| Citric Acid SCHEMBL20456925 | 0.98 | CA4 (0.59) | CA4MEN1LMNAKMT2ACYP3A4 | |
| Citric Acid SCHEMBL3998443 | 0.96 | CA4 (0.57) | CA4MEN1LMNAKMT2ACYP3A4 | |
| Citric Acid SCHEMBL275857 | 0.96 | CA4 (0.57) | CA4MEN1LMNAKMT2ACYP3A4 | |
| Citric Acid SCHEMBL31726489 | 0.96 | CA4 (0.57) | CA4MEN1LMNAKMT2ACYP3A4 | |
| Citric Acid SCHEMBL275860 | 0.96 | CA4 (0.57) | CA4MEN1LMNAKMT2ACYP3A4 | |
| Citric Acid SCHEMBL3871318 | 0.96 | CA4 (0.57) | CA4MEN1LMNAKMT2ACYP3A4 | |
| Citric Acid SCHEMBL15323424 | 0.96 | CA4 (0.57) | CA4MEN1LMNAKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 684 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551441-B2 | Water soluble silicon-containing granulate | BIO MINERALS NV (BE) | 2026-02-17 | — | — | US | claimed |
| EP-4614632-A1 | DEEP EUTECTIC SOLVENTS-BASED ELECTROLYTE COMPOSITIONS | BeFC (FR) | 2025-09-10 | — | — | EP | claimed |
| US-20250073175-A1 | Intra-Dosage Form Coatings and Applications Thereof | BALCHEM CORPORATION | 2025-03-06 | — | — | US | claimed |
| CN-119529137-A | Natural rubber solidification system, natural rubber, and preparation method and application thereof | 中国化工集团曙光橡胶工业研究设计院有限公司 | 2025-02-28 | — | — | CN | claimed |
| EP-4489731-A2 | INTRA-DOSAGE FORM COATINGS AND APPLICATIONS THEREOF | Balchem Corporation (US) | 2025-01-15 | — | — | EP | claimed |
| CN-119285754-A | Method for extracting collagen from fish skin | 浙江工商大学 | 2025-01-10 | — | — | CN | claimed |
| US-12171224-B2 | Choline salt and ammonium-free adjuvants for water conditioning and agricultural formulations | SPECIALTY OPERATIONS FRANCE (FR) | 2024-12-24 | — | — | US | claimed |
| CN-119157034-A | Planting method for preventing and controlling rice blast | 黑龙江省农业科学院佳木斯分院 | 2024-12-20 | — | — | CN | claimed |
| US-20240408130-A1 | Combination of Silicon and Magnesium for the Prevention and Treatment of Muscle Cramps | BIO MINERALS N.V. (BE) | 2024-12-12 | — | — | US | claimed |
| CN-118946346-A | Inner coating for dosage forms and use thereof | 百尔康公司 | 2024-11-12 | — | — | CN | claimed |
| WO-1992013468-A1 | NOVEL CHOLINE-CONTAINING COMPOSITIONS AS SALT SUBSTITUTES AND ENHANCERS AND METHOD OF PREPARATION | INTERNEURON PHARMACEUTICALS INCORPORATED (US) | 1992-08-20 | — | — | WO | claimed |
| EP-0389667-A2 | Use of lecithin to restore olfaction and taste | PHARMACAPS, INC. (US) | 1990-10-03 | — | — | EP | claimed |
| US-4948589-A | CHOLINE COATED WITH HYDROPHOBIC FILM FOR DELAYED DISSOLVING | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1990-08-14 | — | — | US | claimed |
| US-4917685-A | POROUS MEMBRANE CONFINING ACTIVE MATERIALS AND STABILIZERS | INTERNATIONAL MINERALS & CHEM. CORP. | 1990-04-17 | — | — | US | claimed |
| US-4816568-A | AMINO ACIDS, POLYPEPTIDES, CHOLINE SALTS | INTERNATIONAL MINERALS & CHEMICAL CORP. (US) | 1989-03-28 | — | — | US | claimed |
| EP-0303746-A1 | Stabilization of growth promoting hormones | Mallinckrodt Group Inc. (US) | 1989-02-22 | — | — | EP | claimed |
| EP-0019054-B1 | NUTRIENT MEDIUM AND ITS USE IN TESTING ANTIMICROBIAL AGENTS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-05-05 | — | — | EP | claimed |
| US-4309205-A | APPLYING AQUEOUS SOLUTION OF CHOLINE SALT TO IMPROVE QUANTITY AND QUALITY OF FLOWERS OR FRUIT | THE STATE OF ISRAEL MINISTRY OF AGRICULTURE (IL) | 1982-01-05 | — | — | US | claimed |
| US-4275154-A | Nutrient medium | HOFFMANN-LA ROCHE INC. (US) | 1981-06-23 | — | — | US | claimed |
| EP-0019054-A1 | Nutrient medium and its use in testing antimicrobial agents | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-11-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12171224-B2 | Choline salt and ammonium-free adjuvants for water conditioning and agricultural formulations | ACHE, PHOSPHO1, CHAT | CA4 1172/4885MEN1 2734/4885LMNA 3927/4885 |
| US-12551441-B2 | Water soluble silicon-containing granulate | SI, GIPR, VIP | CA4 1064/4885MEN1 2488/4885LMNA 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.